Author:
Sierra-Sánchez Jesús F.,González-Carrascosa Triana
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference5 articles.
1. Holweger K, Lipp HP, Beijnen JH et al (2010) Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin. Cancer Chemother Pharmacol. doi: 10.1007/s00280-010-1537-0 (Published on line on 07 December 2010)
2. Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS (2009) Chronic kidney disease epidemiology collaboration. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 54(1):33–42 (Epub 2009 May 17)
3. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756
4. Romero I, Perayre M, Roca M, Rey M, Martin-Comin J, Clopés A (2009) Comparación de las dosis de carboplatino obtenidas mediante la estimación de la tasa de filtración glomerular. In: 54th Congreso de la Sociedad Española de Farmacia Hospitalaria [Abstract]
5. De Jonge ME, Mathot RA, Van Dam SM, Beijnen JH, Rodenjuis S (2002) Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 50:251–255